CAPR
Capricor Therapeutics Inc
8.60$
-1.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 99.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.1% | 93.9% | 94.9% | 98.1% | 95.5% | 95.8% | 66.5% | 85.1% | 87.1% | 96.6% | 96.6% | 91.6% | 94.9% | 97.3% | 88.2% | 85.6% | 86.6% | 95.8% | 90.7% | |
| – | 92.4% | 64.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.0% | 85.5% | 87.7% | 92.1% | 75.7% | 3.1% | 31.2% | 58.9% | 84.4% | 86.4% | 37.7% | 46.1% | 35.1% | 94.4% | 84.4% | 19.2% | 25.0% | 6.6% | 80.9% | |
| – | 92.4% | 64.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.0% | 85.5% | 87.7% | 92.1% | 75.7% | 80.4% | 37.1% | 58.9% | 84.4% | 86.4% | 86.8% | 78.5% | 88.9% | 94.4% | 84.4% | 82.7% | 67.2% | 88.9% | 89.4% | |
| – | 7.0% | 35.8% | – | – | – | – | – | – | – | – | – | – | 14.6% | 0.0% | 2.6% | 1.3% | 1.2% | 2.1% | 2.2% | 0.8% | 0.2% | 0.9% | 1.1% | 17.7% | 6.1% | 0.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | -14.1% | 25.3% | 21.8% | 0.0% | 7.2% | -5.2% | 3.1% | -5.9% | -0.2% | 0.0% | 0.0% | 0.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.7% | 0.1% | 1.3% | 1.7% | 2.0% | 2.3% | 2.3% | 6.2% | 4.0% | 2.5% | 11.2% | 9.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -537.7% | -58.4% | -6.2% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 1.5% | 3.3% | 3.0% | – | 0.0% | 3.3% | 31.7% | 12.8% | 10.5% | 0.8% | 0.6% | 2.2% | 0.1% | 6.3% | – | – | – | – | – | |
| 318.0% | 6.3% | 3,779.8% | 98,216.0% | 3,870.7% | 9,354.0% | 27,724.2% | 3,209.0% | 11.1% | 20.7% | 17.6% | 29.2% | 39.5% | 9.8% | 109.7% | 145.8% | 106.4% | 121.4% | 31.0% | 50.1% | 38.5% | 18.5% | 24.1% | 76.5% | 61.5% | 14.7% | 14.1% | |
| 318.0% | 6.3% | 3,779.8% | 98,216.0% | 3,870.7% | 9,354.0% | 27,724.2% | 3,209.0% | 11.1% | 20.7% | 17.6% | 29.2% | 39.5% | 9.8% | 37.1% | 46.2% | 40.6% | 26.1% | 10.3% | 13.6% | 8.1% | 8.6% | 10.0% | 47.1% | 53.2% | 12.3% | 10.1% | |
| – | – | – | 30,636.0% | 3,425.7% | 8,188.7% | 24,709.6% | 2,970.2% | – | – | – | – | – | – | – | 67.2% | 5.7% | 74.2% | – | – | – | 0.7% | 1.0% | 1.4% | 1.3% | 0.5% | 1.0% | |
| 318.0% | 6.3% | 3,409.5% | 37,860.0% | 445.0% | 1,165.4% | 3,014.6% | 216.1% | 3.9% | 11.6% | 4.2% | 9.1% | 31.9% | 4.9% | 29.4% | 12.5% | 15.7% | 16.2% | 10.3% | 13.6% | 8.1% | 7.9% | 9.0% | 9.7% | 10.6% | 1.9% | 0.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 71.5% | 67.2% | 57.0% | 90.7% | 20.7% | 36.5% | 30.4% | 0.2% | 8.2% | 6.7% | – | – | – | |
| -218.0% | 93.7% | -3,679.8% | -98,116.0% | -3,770.7% | -9,254.0% | -27,624.2% | -3,209.0% | 88.9% | 79.3% | 82.4% | 70.8% | 60.5% | 90.2% | -9.7% | -45.8% | -6.4% | -21.4% | 69.0% | 49.9% | 61.5% | 81.5% | 75.9% | 23.5% | 38.5% | 85.3% | 85.9% | |
| -253.4% | -261.1% | -24,502.9% | -300,516.0% | -8,460.2% | -17,222.5% | -45,631.3% | -4,513.8% | -75.5% | -404.4% | -936.5% | -1,089.2% | -3,266.0% | -132.9% | -290.7% | -163.7% | -218.9% | -287.9% | -316.8% | -721.7% | -669.3% | -254.3% | -261.5% | -273.6% | -271.3% | -117.2% | -85.7% | |
| 485.9% | 9.6% | 621.4% | 6,040.0% | 139.9% | 237.8% | 537.4% | 656.9% | 0.2% | 0.7% | 1.4% | 1.8% | 5.4% | 1.6% | 19.0% | 8.6% | 9.9% | 9.9% | 16.5% | 31.8% | 33.4% | 45.0% | 55.9% | 49.0% | 45.6% | 20.7% | 13.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.